Your specialist will help design a plan that fits your needs
Wong, PhD, MPH, a professor of medicine at the University of California, Irvine School of Medicine, and colleagues noted that the impact glucagon-like peptide 1 (GLP-1) receptor agonists have on weight loss have recently generated interest and investigation. Semaglutide activates GLP-1 receptors, improving incretin function and insulin secretion (glucose-dependent), inhibiting glucagon release and suppressing hepatic gluconeogenesis, resulting in reductions in both fasting as well as postprandial glucose, they wrote in Cardiovascular Drugs and Therapy
Instead, it feels manageable, structured, and realistic
Schlienger JL, Monnier L (2023) Co-agonistes des rcepteurs du GIP et du GLP-1: une innovation thrapeutique majeure dans le traitement du diabte de type 2